Phase I/II Study of TLC D-99 Plus Herceptin as First or Second Line Therapy for Patients With Locally Advanced Inflammatory or Metastatic Breast Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effectiveness of liposomal doxorubicin and trastuzumab in treating women who have locally advanced, inflammatory, or metastatic breast cancer.
详细描述
OBJECTIVES:
- Determine the safety, especially the cardiac safety, of doxorubicin HCl liposome and trastuzumab (Herceptin) as first- or second-line therapy in women with metastatic, inflammatory, or locally advanced breast cancer.
OUTLINE: Patients are stratified according to prior anthracycline therapy (yes vs no).
Patients receive doxorubicin HCl liposome IV over 1 hour followed 30 minutes later by trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15. Treatment continues every 21 days in the absence of unacceptable toxicity or disease progression.
Patients are followed for at least 3 months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the breast that has been treated with no more than 1 prior systemic cytotoxic regimen
- •Overexpression of HER2 protein (2+ or 3+)
- •Evaluable disease
- •History of brain metastases allowed if off steroids and asymptomatic, with a 3 month or greater interval since last dose of brain irradiation, and no evidence of progression
- •Hormone receptor status:
- •Not specified
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Menopausal status:
- •Not specified
- •Performance status:
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Absolute neutrophil count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Hemoglobin at least 10 g/dL
- •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- •AST or ALT no greater than 4 times ULN
- •Cardiovascular:
- •Adequate cardiac function
- •LVEF at least 50% predicted or lower limit of normal
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No other concurrent medical or psychological condition that would preclude study compliance
- •No history of hypersensitivity to anthracyclines, eggs, or egg products
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Prior trastuzumab (Herceptin) allowed
- •Chemotherapy:
- •See Disease Characteristics
- •At least 3 weeks since prior antineoplastic therapy
- •No more than 1 prior systemic cytotoxic regimen for locally advanced, metastatic, or inflammatory breast cancer
- •No prior anthracyclines greater than 240 mg/m2
- •No other concurrent antineoplastic agents
- •No concurrent treatment with other liposomal products other than doxorubicin HCl liposome
- •Endocrine therapy:
- •See Disease Characteristics
- •At least 3 weeks since prior hormonal agents
- •No concurrent hormonal therapy
- •Radiotherapy:
- •See Disease Characteristics
- •Not specified
- •At least 3 weeks since other prior investigational drugs
排除标准
- 未提供